ClinicalTrials.gg
CompletedNCT01294254OleoSplitUpdated Apr 3, 2015

Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

A Phase 2 interventional study of Oleogel-S10 and Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site in Accelerating the Epithelialization of Split Thickness Skin Graft, sponsored by Birken AG. Completed at 2 sites in Germany. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2015-04-03.

Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

In this study the wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone will be investigated.

Read the detailed description

As a first step, an adequate size of the wound healing dressing (Mepilex) is taken and cut in half. Then, half of the SSG (split skin graft) wound is covered conventionally by applying one half of the Mepilex cut. Afterwards Oleogel-S10 is applied to the other half of the Mepilex cut, which is used to cover the other half of the SSG wound. Both parts of the Mepilex dressings are then covered by an additional conventional dressing.

Oleogel-S10 is always applied to the same part of the SSG wound for each patient, respectively, depending on the randomization of the patient, either towards the periphery of the body, i.e. the lower part of the leg, or towards the centre part of the body, i.e. the upper part of the leg. In order to avoid a confusion about which part has to be treated with Oleogel-S10, the healthy skin next to the SSG wound will be marked with ink for indication of the Oleogel-treated part of the wound.

Each day during the treatment period, whenever the wound dressing is changed, a clinical examination and assessment of the progress of epithelialization of the SSG wound will be conducted, including evaluation of tolerance, and photos of the wound without dressing will be taken.

A blinded assessment of the efficacy is conducted by two independent investigators using the macro-photos of every day, when wound dressings were changed, and a final examination is done. In this assessment, the third part of the SSG wound that is in between the left and right parts is neglected.

02

Conditions studied

  • Accelerating the Epithelialization of Split Thickness Skin Graft

Keywords

  • wound reepithelialization
03

In context

Lead sponsor

Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Birken AG became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may participate in the study if they have/are

  • Patients aged 18-95 years who have provided written .
  • Patients requiring skin grafting due to burns, trauma, chronic venous ulcers, or surgical removal of cutaneous with a donor site expected to be between 8 and 200 cm2 on a non-articulated area.
  • Patient is prepared to comply with all study requirements, including the following:

    • Application of Oleogel-S10 on the SSG at every change of wound dressing;
    • Regular clinic visits during the treatment period, and follow-up period.
  • Negative pregnancy test of women of performed within 7 days prior to the start of treatment.
  • Women of childbearing potential must agree to use an effective method of (Pearl-Index \< 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter.
  • Men must agree to use an effective method of contraception during treatment and for at least 6 months thereafter.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they have/are

  • burns involving more than 15% of their total body area;
  • sepsis, haemodynamic instability requiring pressor support or positive blood microbiology cultures within 48h of surgery;
  • inhalation injury requiring artificial respiratory assistance;
  • requiring skin grafts following removal of suspicious skin lesions;
  • received treatment with systemic during the 30 days prior to surgery;
  • uncontrolled diabetes or diabetic ulcers;
  • diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy;
  • previously skin grafts harvested from the area to be studied;
  • a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial;
  • a history of to any of the drugs or surgical dressings to be used in this trial;
  • known multiple allergic disorders;
  • taking, or have taken, any drugs within 3 months prior to the screening visit;
  • undergoing investigations or changes in management for an existing medical condition;
  • not likely to complete the trial for whatever reason.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    experimantal: wound site will be treated with Oleogel-S10

    The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10. Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg * Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily) * Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

    Drug: Oleogel-S10

  • Active comparator
    Moist wound healing dressing alone

    Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

    Procedure: Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

Interventions

  • DrugOleogel-S10

    Drug pages: Episalvan · Birch triterpenes

    Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)

  • ProcedureMoist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

    wound is covered conventionally by applying one half of the Mepilex cut

06

What researchers measure

Primary outcomes

  1. Wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone during a treatment period of 14 days.

    Time frame: 14 days

Secondary outcomes

  1. • Size of wound epithelialization

    Time frame: 3 months

  2. • Touch sensitivity: Sensitivity of the SSG wound by touching it with a spatula or cotton swabs (visual analogue scale from "no" = 0 to "severe" = "10"

    Time frame: 3 months

  3. • Pruritus (visual analogue scale from "no" = 0 to "strong" = "10")

    Time frame: 3 months

  4. • Reconstitution of the skin (% reepithelization) 3 months after skin explantation

    Evaluation of wound closure by assessment of epithelialization (in %)

    Time frame: 3 months

07

Study locations

2 sites
  • Universitäts-Hautklinik Freiburg
    Freiburg, 79104, Germany
  • Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald
    Greifswald, 17475, Germany
08

References and documents

Publications

  • Metelmann HR, Brandner JM, Schumann H, Bross F, Fimmers R, Bottger K, Scheffler A, Podmelle F. Accelerated reepithelialization by triterpenes: proof of concept in the healing of surgical skin lesions. Skin Pharmacol Physiol. 2015;28(1):1-11. doi: 10.1159/000357501. Epub 2014 Jul 15. PubMed 25034442 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2010
First posted
Feb 11, 2011
Start
Apr 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Last update
Apr 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01294254
Lead sponsor
Birken AG
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Apr 2010
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Apr 3, 2015

Study contacts

Hans Robert Metelmann, Prof. Dr. med.
principal investigator · University Hospital of Ernst-Moritz-Arndt-University Greifswald

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Episalvan · Birch triterpenes

Start the discussion